Plus Therapeutics, Inc. - Special Call Transcript
Good afternoon. Welcome to our investor update call on our Phase I ReSPECT trial for recurrent glioblastoma. As a reminder, please review our forward-looking statements language that can be found in this investor deck or other investor-oriented presentations.
My name is Marc Hedrick. I'm President and CEO of Plus Therapeutics. I'll lead the call through our planned 1-hour agenda. First, I'll present a brief overview on Plus, then the team will talk about recurrent glioblastoma as a disease target. And then we'll talk about the results of the ReSPECT trial thus far, and then we'll hear from a patient. Following the patient, we'll then have time for Q&A.
Joining me this afternoon are Dr. Gregory Stein, Senior Vice President of Clinical Development at Plus Therapeutics; and also, we're fortunate to have Dr. Andrew Brenner, Associate Professor of Medicine, Neurology and Neurosurgery at UT Health Science Center at San Antonio.
So with regard to Plus Therapeutics, our focus is on the discovering, developing
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
